GSK plc/ US37733W2044 /
6/3/2024 10:10:00 PM | Chg. -3.89 | Volume | Bid1:57:21 AM | Ask1:57:21 AM | High | Low |
---|---|---|---|---|---|---|
40.88USD | -8.69% | 13.48 mill. Turnover: 401.35 mill. |
40.88Bid Size: 100 | 41.00Ask Size: 100 | 41.72 | 40.51 |
GlobeNewswire
6/3
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
5/30
SERB Pharmaceuticals appoints Vanessa Wolfeler as CEO to drive next stage of the company’s growth
GlobeNewswire
5/23
Ivy Brain Tumor Center announces Phase 0/2 clinical readout of niraparib indicating significant impr...
GlobeNewswire
5/21
Engitix Announces Appointment of Matthew Edwards Ph.D., as SVP Discovery and Emma Huang Ph.D., as VP...
GlobeNewswire
5/16
Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference
GlobeNewswire
5/15
Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update
GlobeNewswire
5/13
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...
GlobeNewswire
5/9
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
5/9
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) ...
GlobeNewswire
5/9
Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sag...
GlobeNewswire
5/9
Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
5/9
Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer
GlobeNewswire
5/9
Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
GlobeNewswire
5/8
SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
5/8
Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wed...